New Simmons Cancer Center research involving investigational drug to target AXL inhibition shows possible benefits for patients with lung adenocarcinomas.
Researchers uncover a key mechanism that regulates PD-L1, a protein that helps tumors evade the immune system and is the target of several immunotherapy drugs.